Life sciences group Sartorius is launching an integrated system for the production and quality control (QC) of autologous cell therapies. The modular Eveo Cell Therapy Platform is designed to address structural manufacturing bottlenecks that limit scalability and patient access to innovative treatments such as CAR-T therapy. With the latest innovations, Sartorius introduces a fundamentally new approach to cell therapy manufacturing and strengthens the company’s position in the dynamic advanced therapeutics market.
Image credit: Sartorius
Cell therapy is redefining medical possibilities. However, manufacturing is complex, capacity limited, and therefore expensive, so it remains available to only a small number of patients. With our integrated platform, we address these structural bottlenecks head-on. By combining raw materials, production equipment, software, and QC assays into a scalable system, customers can scale production, significantly reduce cost per dose, and shorten patient IV-to-IV time. ”
René Faber, member of the Sartorius Board of Directors
Traditional manufacturing models for autologous cell therapies rely on centralized, purpose-built facilities, requiring significant greenfield investments, staff recruitment and training, and multi-year construction phases. Nevertheless, approximately 60% of regulatory disruptions in cell therapy production are caused by manufacturing and process-related issues.
The new Eveo platform addresses these challenges by integrating cell selection, activation, genetic modification, expansion, washing and concentration, and final formulation into a closed system using a range of Sartorius solutions, from critical raw materials to bioreactors and separation technologies. The system’s compact design supports implementation in existing facilities by existing staff, enables operation in subclassified environments, and supports centralized and distributed manufacturing models.
Sartorius tested the Eveo platform in collaboration with ElevateBio, a leading cell therapy CDMO, and other partners. The pilot was successful, and the system performed as designed and demonstrated real-world applicability. The multi-parallel configuration allows one operator to process eight patient batches simultaneously in the same clean room space traditionally required for two batches. Assuming a production time of approximately 7 days per batch and 50 weeks of production per year, Eveo enables the production of more than 350 doses per year on a production area that is approximately 100 doses today (almost four times more). Financial modeling confirms that the platform can reduce manufacturing costs by approximately 90%.
Quality control is also a major bottleneck in cell therapy manufacturing and launch. With Sartorius’ live-cell imaging and high-throughput flow cytometry capabilities included in the Eveo platform, this technology addresses key analytical challenges and enables accessibility.
Sartorius plans to begin accepting orders for the Eveo cell therapy platform in September 2026, with first deliveries expected in 2027. ElevateBio is a preferred partner and will be granted access to one of the first Eveo platforms for manufacturing customers.
